Recent discussions on X about Tempus AI, Inc. (TEM) have been fueled by the company’s latest earnings report and an upgraded financial outlook for 2025. Many users are highlighting the impressive revenue growth and a significant reduction in net loss, sparking enthusiasm about the company's trajectory. The buzz intensified with a recent acquisition announcement, which some argue could further solidify TEM’s position in the healthcare AI space.
However, not all sentiments are glowing, as lingering concerns from a critical short report earlier this year continue to surface in conversations. Some posts on X point to skepticism about revenue sources and leadership, while others focus on technical price trends that suggest caution ahead. This mix of optimism and wariness keeps the dialogue around TEM lively and multifaceted.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI, Inc. Insider Trading Activity
Tempus AI, Inc. insiders have traded $TEM stock on the open market 142 times in the past 6 months. Of those trades, 0 have been purchases and 142 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
- ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 48 sales selling 4,753,039 shares for an estimated $279,153,227.
- RYAN FUKUSHIMA (Chief Operating Officer) has made 0 purchases and 18 sales selling 90,280 shares for an estimated $5,413,740.
- ERIK PHELPS (EVP & Chief Admin & Legal Off) has made 0 purchases and 8 sales selling 63,396 shares for an estimated $4,529,084.
- THEODORE LEONSIS has made 0 purchases and 2 sales selling 44,770 shares for an estimated $3,126,620.
- JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 12 sales selling 53,679 shares for an estimated $3,083,502.
- SCOTT GOTTLIEB has made 0 purchases and 9 sales selling 55,675 shares for an estimated $2,674,142.
- ANDREW POLOVIN (EVP and General Counsel) has made 0 purchases and 13 sales selling 40,584 shares for an estimated $2,376,777.
- WAYNE A.I. FREDERICK has made 0 purchases and 6 sales selling 12,000 shares for an estimated $576,278.
- RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 5 sales selling 7,977 shares for an estimated $526,163.
- JENNIFER A DOUDNA has made 0 purchases and 7 sales selling 10,491 shares for an estimated $524,086.
- NADJA WEST has made 0 purchases and 10 sales selling 8,443 shares for an estimated $414,309.
- DAVID R EPSTEIN has made 0 purchases and 4 sales selling 1,980 shares for an estimated $100,365.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Tempus AI, Inc. Government Contracts
We have seen $5,785,617 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TUMOR NORMAL MATCHED GENOMIC TESTING SERVICES: $5,718,045
- DNA METHYLATION SERVICES FOR TELECONFERENCING EXERCISE STUDY IN HIV + PATIENTS: $67,572
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Tempus AI, Inc. Analyst Ratings
Wall Street analysts have issued reports on $TEM in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 08/20/2025
- Morgan Stanley issued a "Overweight" rating on 08/12/2025
- Guggenheim issued a "Buy" rating on 06/30/2025
- Needham issued a "Buy" rating on 05/07/2025
To track analyst ratings and price targets for Tempus AI, Inc., check out Quiver Quantitative's $TEM forecast page.
Tempus AI, Inc. Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 6 analysts offer price targets for $TEM in the last 6 months, with a median target of $70.0.
Here are some recent targets:
- Mark Massaro from BTIG set a target price of $85.0 on 08/20/2025
- Tejas Savant from Morgan Stanley set a target price of $68.0 on 08/12/2025
- Subbu Nambi from Guggenheim set a target price of $75.0 on 06/30/2025
- Michael Ryskin from B of A Securities set a target price of $70.0 on 06/25/2025
- David Westenberg from Piper Sandler set a target price of $70.0 on 05/15/2025
- Ryan MacDonald from Needham set a target price of $70.0 on 05/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
